LPA and familial hypercholesterolemia: Moreover, Inclisiran therapy was shown to be associated with Lp(a) reduction by 13.5% among patients with heterozygous familial hypercholesterolemia in the ORION-9 trial, by 21.9% in patients with established ASCVD in the ORION-10 trial, and by 18.6% among patients with ASCVD or an ASCVD equivalent in ORION-11 [59,60].